Clinical and Experimental Dermatology

Biography

Biography: Andrew Leask

Abstract

Melanoma, the second most common invasive cancer in young adults, is highly metastatic: ~5% of patients diagnosed with metastatic melanoma survive for 5 years after diagnosis. 40-60% of all cutaneous melanoma patients possess mutations in BRAF; in these patients, tumors shrink in response to the BRAF inhibitors. However, patients develop resistance to these drugs, necessitating the development of alternative therapeutic targets. The matricellular protein connective tissue growth factor (CCN2) is overexpressed in melanoma; however, how CCN2 contributes to melanoma progression is unclear. Herein, we use melanoma cell lines and mice in which CCN2 is deleted in the tumor stroma to demonstrate that loss of CCN2 in the tumor microenvironment impedes melanoma invasion. Specifically, loss of CCN2 in melanoma cells diminished their ability to invade through collagen in vitro and loss of fibroblast derived CCN2 decreased metastases of melanoma cells from the skin to the lungs in vivo. CCN2 deficient B16(F10) cells showed reduced expression of periostin; addition of recombinant periostin rescued the in vitro invasion defect of these cells. Analysis of CCN2 deficient mice confirmed loss of periostin expression in the absence of CCN2. CCN2 and periostin mRNA levels are positively correlated with each other and with the stromal composition of human melanoma lesions but not BRAF mutations. These results are consistent with the idea that metastatic ability results from CCN2 mediated interactions between tumor cells and the stroma. CCN2 promotes invasion and metastasis via periostin and should be further evaluated as a possible therapeutic target for BRAF inhibitor-resistant melanoma.